Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems

An ongoing need for new cancer therapeutics exists, especially ones that specifically home and target triple-negative breast cancer. Because triple-negative breast cancer express low or are devoid of estrogen, progesterone, or Her2/Neu receptors, another target must be used for advanced drug deliver...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:NPJ Precis Oncol
Autors principals: Jenkins, Samir V., Nima, Zeid A., Vang, Kieng B., Kannarpady, Ganesh, Nedosekin, Dmitry A., Zharov, Vladimir P., Griffin, Robert J., Biris, Alexandru S., Dings, Ruud P. M.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5871908/
https://ncbi.nlm.nih.gov/pubmed/29872709
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-017-0030-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars